Aurinia Pharmaceuticals Inc. (AUPH) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
4464 Markham Street
Edmonton, BC V8Z 7X8
Canada
Phone
12507084272
Sector
Healthcare
Industry
Biotechnology
Employees
130
First IPO Date
September 03, 2014
| Name | Title | Pay | Year Born |
| Kevin C. Tang | Chairman & CEO | 0 | 1967 |
| Michael S. Hearne | Chief Financial Officer | 866,870 | 1963 |
| Stephen Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer | 923,480 | 1982 |
| Peter S. Greenleaf | Consultant | 1.7M | 1970 |
| Stewart Kroll | Chief Development Officer | 0 | 1959 |
| Thomas Wei | Chief Scientific Officer | 0 | 1976 |
| Andrea Levin Christopher | Executive Director of Corporate Communications & Investor Relations | 0 | N/A |
| Ryan Cole | Chief Operating Officer | 0 | 1987 |
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.